Loading...

Grant D. Lawless, RPh, MD, FACP

Title(s)Associate Professor, Pharmaceutical & Health Economics
Phone+1 213 821 6181
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Oderda GM, Lawless GD, Wright GC, Nussbaum SR, Elder R, Kim K, Brixner DI. The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. Per Med. 2018 07 01; 15(4):291-301. PMID: 29693487.
      View in: PubMed
    2. Zweigenhaft B, Bosserman L, Kenney JT, Lawless GD, Marsland TA, Deligdish CK, Burgoyne DS, Knopf KB, Long DM, McKercher P, Owens GM, Hennessy JE, Lang JR, Malin J, Natelson L, Palmgren MC, Slotnik J, Shockney LD, Vogenberg FR. Defining Value in Cancer Care: AVBCC 2013 Steering Committee Report. Am Health Drug Benefits. 2013 Jul; 6(5):236-46. PMID: 24991360.
      View in: PubMed
    3. Short LJ, Fisher MD, Wahl PM, Kelly MB, Lawless GD, White S, Rodriguez NA, Willey VJ, Brawley OW. Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention. Cancer. 2010 Jan 01; 116(1):193-202. PMID: 19877115.
      View in: PubMed
    4. Lawless GD. The working patient with cancer: implications for payers and employers. Am Health Drug Benefits. 2009 Jun; 2(4):168-73. PMID: 25126288.
      View in: PubMed
    5. Joyce GF, Goldman DP, Karaca-Mandic P, Lawless GD. Impact of specialty drugs on the use of other medical services. Am J Manag Care. 2008 Dec; 14(12):821-8. PMID: 19067499.
      View in: PubMed
    6. Willey VJ, Kopenski F, Lawless GD. Beyond the myths: finding benefit design solutions that address the true costs of high healthcare use. Am J Manag Care. 2008 Jul; 14(8 Suppl):S252-63. PMID: 18672956.
      View in: PubMed
    7. Willey VJ, Pollack MF, Lednar WM, Yang WN, Kennedy C, Lawless G. Costs of severely ill members and specialty medication use in a commercially insured population. Health Aff (Millwood). 2008 May-Jun; 27(3):824-34. PMID: 18474976.
      View in: PubMed
    8. Owens G, Emons MF, Christian-Herman J, Lawless G. Current trends in pharmacy benefit designs: a threat to disease management in chronic complex diseases. Dis Manag. 2007 Apr; 10(2):74-82. PMID: 17444792.
      View in: PubMed
    9. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006 Sep-Oct; 25(5):1319-31. PMID: 16966729.
      View in: PubMed
    10. Morrow T, Siegel M, Boone S, Lawless G, Carter W. Chemotherapy dose intensity determination as a quality of care measure for managed care organizations in the treatment of early-stage breast cancer. Am J Med Qual. 2002 Nov-Dec; 17(6):218-24. PMID: 12487337.
      View in: PubMed
    11. Halbert RJ, Zaher C, Wade S, Malin J, Lawless GD, Dubois RW. Outpatient cancer drug costs: changes, drivers, and the future. Cancer. 2002 Feb 15; 94(4):1142-50. PMID: 11920485.
      View in: PubMed
    12. Picozzi VJ, Pohlman BL, Morrison VA, Lawless GD, Lee MW, Kerr RO, Ford JM, Delgado DJ, Fridman M, Carter WB. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Williston Park). 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PMID: 11702959.
      View in: PubMed
    13. Link BK, Budd GT, Scott S, Dickman E, Paul D, Lawless G, Lee MW, Fridman M, Ford J, Carter WB. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer. 2001 Sep 15; 92(6):1354-67. PMID: 11745211.
      View in: PubMed
    14. Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001 Jun; 2(1):47-56. PMID: 11707870.
      View in: PubMed
    15. Lawless GD. A managed care approach to outpatient review. Qual Assur Util Rev. 1990 May; 5(2):53-7. PMID: 2136665.
      View in: PubMed
    16. Lawless GD. Cost containment through outpatient substance abuse services. Empl Benefits J. 1990 Mar; 15(1):6-10. PMID: 10170526.
      View in: PubMed